Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P van Meerbeeck

Showing results (161-170 of 250) with videos related to

Pageof 25
Sort By:
Journal of Medical Screening|December 30, 2025
Design and rationale of the ZORALCS study: An implementation study of lung cancer screening by low-dose computed tomography coupled to a smoking cessation randomized controlled trial in the Flemish regionCharlotte Theuns, Amber Gerris, Jan P van Meerbeeck, et al.
Journal of Breath Research|September 8, 2023
Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: baseline resultsKathleen Zwijsen, Eline Schillebeeckx, Eline Janssens, et al.
Clinical Lung Cancer|February 13, 2017
Addressing the Palliative Setting in Advanced Lung Cancer Should Not Remain a Barrier: A Multicenter StudyAnnelies Janssens, Sofie Derijcke, Anneke Lefebure, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2022
The need for a comprehensive and integrated approach to lung cancer policy in EuropeMonica Racovita, Eleanor Wheeler, Suzanne Wait, et al.
Oncotarget|January 27, 2018
Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesotheliomaMarieke Hylebos, Guy Van Camp, Geert Vandeweyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2000
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patientsG Giaccone, E F Smit, J P van Meerbeeck, et al.
International Journal of Molecular Sciences|August 29, 2019
Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint ExpressionElly Marcq, Jonas Rm Van Audenaerde, Jorrit De Waele, et al.
Cancer|June 22, 1999
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative GroupJ P van Meerbeeck, P Baas, C Debruyne, et al.
Translational Lung Cancer Research|August 2, 2019
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trialRobert A Belderbos, Paul Baas, Rossana Berardi, et al.
Oncotarget|December 7, 2017
Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control studyKevin Lamote, Paul Brinkman, Lore Vandermeersch, et al.
Pageof 25

Showing results (161-170 of 250) with videos related to

Sort By:
Pageof 25
Journal of Medical Screening|December 30, 2025
Design and rationale of the ZORALCS study: An implementation study of lung cancer screening by low-dose computed tomography coupled to a smoking cessation randomized controlled trial in the Flemish regionCharlotte Theuns, Amber Gerris, Jan P van Meerbeeck, et al.
Journal of Breath Research|September 8, 2023
Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: baseline resultsKathleen Zwijsen, Eline Schillebeeckx, Eline Janssens, et al.
Clinical Lung Cancer|February 13, 2017
Addressing the Palliative Setting in Advanced Lung Cancer Should Not Remain a Barrier: A Multicenter StudyAnnelies Janssens, Sofie Derijcke, Anneke Lefebure, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2022
The need for a comprehensive and integrated approach to lung cancer policy in EuropeMonica Racovita, Eleanor Wheeler, Suzanne Wait, et al.
Oncotarget|January 27, 2018
Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesotheliomaMarieke Hylebos, Guy Van Camp, Geert Vandeweyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2000
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patientsG Giaccone, E F Smit, J P van Meerbeeck, et al.
International Journal of Molecular Sciences|August 29, 2019
Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint ExpressionElly Marcq, Jonas Rm Van Audenaerde, Jorrit De Waele, et al.
Cancer|June 22, 1999
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative GroupJ P van Meerbeeck, P Baas, C Debruyne, et al.
Translational Lung Cancer Research|August 2, 2019
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trialRobert A Belderbos, Paul Baas, Rossana Berardi, et al.
Oncotarget|December 7, 2017
Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control studyKevin Lamote, Paul Brinkman, Lore Vandermeersch, et al.
Pageof 25